Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 3

Targeted Oncology

In the phase 3 ARASENS study, the use of darolutamide with docetaxel and androgen deprivation therapy demonstrated an overall survival advantage for patients with metastatic hormone-sensitive prostate cancer.

  • 123456 Profile photo of Madelyn

    Is triplet therapy the new doublet for metastatic hormone sensitive prostate cancer?